We are live on ! Find out more
IGC icon

IGC Pharma
IGC

20 hedge funds and large institutions have $3.07M invested in IGC Pharma in 2018 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,931% more capital invested

Capital invested by funds: $151K → $3.07M (+$2.92M)

400% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 3

150% more funds holding

Funds holding: 8 → 20 (+12)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
20
Holders Change
+12
Holders Change %
+150%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CFA
Carroll Financial Associates
North Carolina
+$223K
2
HSBC Holdings
HSBC Holdings
United Kingdom
+$62.1K
3
Jane Street
Jane Street
New York
+$22.1K
4
IG
ING Group
Netherlands
+$15.6K
5
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
+$12.2K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$57K
2
VF
Virtu Financial
New York
-$22K
3
GWM
Geneos Wealth Management
Colorado
-$9K
4
UBS Group
UBS Group
Switzerland
-$608
Name Holding Trade Value Shares
Change 		Change in
Stake
CFA
1
Carroll Financial Associates
North Carolina
$1.39M +$223K +215,000 New
Creative Planning
2
Creative Planning
Kansas
$420K – – –
HSBC Holdings
3
HSBC Holdings
United Kingdom
$385K +$62.1K +59,730 New
SB
4
Suntrust Banks
Georgia
$355K – – –
Jane Street
5
Jane Street
New York
$137K +$22.1K +21,309 New
IG
6
ING Group
Netherlands
$97K +$15.6K +15,000 New
Cambridge Investment Research Advisors
7
Cambridge Investment Research Advisors
Iowa
$75K +$12.2K +11,700 New
LTFS
8
Ladenburg Thalmann Financial Services
Florida
$63K +$7.14K +6,875 +458%
AG
9
Advisor Group
Arizona
$33K +$5.44K +5,232 New
CAM
10
CenterStar Asset Management
Illinois
$30K – – –
UBS Group
11
UBS Group
Switzerland
$19K -$608 -585 -16%
Citigroup
12
Citigroup
New York
$19K +$3.12K +3,000 New
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$11K – – –
PA
14
Parallel Advisors
California
$11K +$1.72K +1,655 New
FANJ
15
Financial Architects (New Jersey)
New Jersey
$6K +$1.04K +1,000 New
OIA
16
Optimum Investment Advisors
Illinois
$6K +$1.04K +1,000 New
ASN
17
Advisory Services Network
Georgia
$5K +$727 +700 New
Morgan Stanley
18
Morgan Stanley
New York
$5K +$753 +725 New
Bank of America
19
Bank of America
North Carolina
$3K +$520 +500 New
Deutsche Bank
20
Deutsche Bank
Germany
$1K +$104 +100 New
Citadel Advisors
21
Citadel Advisors
Florida
– -$57K -114,693 Closed
VF
22
Virtu Financial
New York
– -$22K -44,012 Closed
GWM
23
Geneos Wealth Management
Colorado
– -$9K -20,000 Closed
VFA
24
Valeo Financial Advisors
Indiana
– +$104 +100 New

IGC Hedge Fund Activity: Q3 2018 in Review

20 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q3 2018, worth a combined $3.07M — up 1,931% from $151K a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new IGC positions and 3 closed out — a net gain of 12 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Carroll Financial Associates, opening a new position worth an estimated $223K. The largest seller was Citadel Advisors, exiting entirely with an estimated $57K sold.

  • 20 institutional investors held IGC Pharma (IGC) as of Q3 2018, up from 8 in Q2 2018.
  • Funds reported $3.07M of IGC Pharma stock for Q3 2018, up 1,931% quarter-over-quarter.
  • 15 funds opened new IGC Pharma positions in Q3 2018 and 3 closed out, a net change of +12 holders.
  • The largest IGC Pharma buyer in Q3 2018 was Carroll Financial Associates, an estimated $223K added.
  • The largest IGC Pharma seller in Q3 2018 was Citadel Advisors, an estimated $57K sold.

Based on aggregated 13F filings for Q3 2018.